Boehringer Ingelheim reviews cough medicine in China

SHANGHAI German pharmaceutical company Boehringer Ingelheim has called a creative review of its US$5 million Mucosolvan cough medicine brand in China, with four agencies, including incumbent Publicis and Y&R, believed to be competing for the account.

by | 04/13/2008

Mucosolvan is the world’s leading cough expectorant.

While Boehringer Ingelheim develops a range of chemical products, including animal health treatments and biopharmaceuticals, human pharmaceuticals account for 95 percent of the company’s sales.

Related Articles

Love, limitations and an AI experiment: Skyn's Valentine's Day campaign

By Nikita Mishra

Droga5 and Accenture Song illustrate the pull of Qiddiya City

By Campaign Staff

BRIEFINGS: AXN wins Toyota sponsorship

Unlike studio-shot ads, we aim to vividly portray our durability tests: Samsonite’s Anushree Tainwala

By Noel D'souza

How to cut cookies with Campaign: Targeting alternatives

By Jessica Heygate

SATELLITE & CABLE: NatGeo reinforces global stance in advertising sales

Empowering China's Gen Z: Apple's new CNY film takes on the touchy topic of insecurities

By Shawn Lim

Hakuhodo, TBWA launch G1 for Toyota

Valuable 500 film spotlights disability inclusion with synchronised swimming

By Charlotte Rawlings

Mars Wrigley refreshes gum brands with quirky 'Chew good' platform

By Marianne Calnan